- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on PD-1 Inhibitor
Total 6182 results
-
The Second Affiliated Hospital of Harbin Medical...UnknownContract Management PD
-
Institute of Oncology LjubljanaUniversity of Ljubljana; Military Medical Academy, Belgrade, SerbiaRecruitingMetastatic Melanoma | Immune Checkpoints Inhibitors | Gastrointestinal Microbiome (Bacterial and Viral) | Exosomal mRNA Expression of PD-L1 and IFNγSlovenia
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Shanghai Zhongshan HospitalActive, not recruitingBiliary Tract Cancer | PD-1 Antibody | Lenvatinib | GemoxChina
-
Beijing Friendship HospitalCompletedCamrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 TherapyChina
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedHealthy Subjects | PK/PDChina
-
University Hospital HeidelbergDepartment of Dermatology, Heidelberg University HospitalCompletedMelanoma | Exercise | PD-1 AntibodiesGermany
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaboratorsRecruiting
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Impatients N.V. trading as myTomorrowsKamada, Ltd.No longer availableAlpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Puerto Rico
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Fudan UniversityNot yet recruitingGastric Cancer | MSI-H | Adjuvant Therapy | PD-1 ImmunotherapyChina
-
Nanjing Medical UniversityCompletedImmune Checkpoint Inhibitor | Endocrine ToxicityChina
-
Hadassah Medical OrganizationRecruitingAminoglycoside Dosing Based on PK/PD CharacteristicsIsrael
-
Groupe Hospitalier Paris Saint JosephCompletedProton Pump InhibitorFrance
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
Sun Yat-sen UniversityRecruitingImmunotherapy | DMMR Colorectal Cancer | Anti PD-1China
-
Meir Medical CenterUnknownThe Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.Israel
-
Cancer Institute and Hospital, Chinese Academy...RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | PertuzumabChina
-
Fudan UniversityRecruitingCarcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKIChina
-
Sun Yat-sen UniversityRecruitingSolid Tumor | Intestinal Flora | Immune Checkpoint InhibitorChina
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
University of Kansas Medical CenterRecruitingHMG-CoA Reductase Inhibitor ToxicityUnited States
-
Mario Negri Institute for Pharmacological ResearchFederico II University; IRCCS MultimedicaCompletedProton Pump Inhibitor | Primary CareItaly
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
The First Hospital of Jilin UniversityActive, not recruitingLocally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | TislelizumabChina
-
Institut Mutualiste MontsourisInstitut CurieRecruitingCancer | Immune Checkpoint Inhibitor | Cardiovascular BiomarkersFrance
-
VA Office of Research and DevelopmentVHA Pharmacy Benefits Management Services VA Center For Medication SafetyCompletedEvaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program (RaPPID)Proton Pump InhibitorsUnited States
-
Groupe Hospitalier Pitie-SalpetriereVanderbilt University Medical CenterCompleted
-
Ospedale Santa Croce-Carle CuneoUnknownPlatelet Aggregation Inhibitors
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Radboud University Medical CenterCompletedProton Pump Inhibitor | Inappropriate Drug Use | Discontinuation | E-healthNetherlands
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaboratorsRecruitingRectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr DeficiencyChina
-
The First Hospital of Jilin UniversityNot yet recruitingLocally Advanced Rectal Cancer | Anti-PD-1 | Total Neoadjuvant TreatmentChina
-
Xuanwu Hospital, BeijingUnknownNon-small Cell Lung Cancer | PD-1 Antibody | Lung Cancer Stage II
-
Gilead SciencesNimbus ApolloCompletedPD Effects of GS-0976 (NDI-010976) on Fractional DNLUnited States
-
Sharp HealthCareNo longer availablePrior Treatment With PD-0325901 With Ongoing Clinical ResponseUnited States
-
Bursa Postgraduate HospitalCompletedContrast Agents and Oral Factor Xa InhibitorTurkey
-
Nantes University HospitalCompletedProton Pump Inhibitors | DeprescriptionFrance
-
Johann Wolfgang Goethe University HospitalWithdrawnSDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV InhibitorsGermany
-
The Affiliated Hospital of Qingdao UniversityUnknownNSCLC Stage IV | PD-1 | ARID1AChina
-
Diwakar DavarMerck Sharp & Dohme LLC; Gateway for Cancer ResearchNot yet recruitingPD-1 Refractory Advanced MelanomaUnited States
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Institut Mutualiste MontsourisRecruitingCancer | Cardiovascular Complication | Immune Checkpoint Inhibitor | Immune-related Adverse EventFrance